z-logo
Premium
Systemic use of non‐biologic agents in orofacial diseases: other immunomodulatory agents
Author(s) -
Georgakopoulou EA,
Scully C
Publication year - 2015
Publication title -
oral diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.953
H-Index - 87
eISSN - 1601-0825
pISSN - 1354-523X
DOI - 10.1111/odi.12172
Subject(s) - medicine , thalidomide , dapsone , apremilast , purine analogue , adverse effect , topical agents , calcineurin , pharmacology , dermatology , immunology , psoriasis , purine , biochemistry , chemistry , psoriatic arthritis , multiple myeloma , enzyme , transplantation
Systemic non‐biologic agents have long been in clinical use in medicine – often with considerable efficacy, albeit with some adverse effects – as with all medications. With the advent of biologic agents, all of which currently are restricted to systemic use, there is a growing need to ensure which agents have the better therapeutic ratio. The non‐biologic agents ( NBA s) include a range of agents, most importantly the corticosteroids (steroids). Previous articles by us in this series have discussed systemic use of corticosteroids and purine synthesis inhibitors; the other immunomodulating agents (calcineurin inhibitors, thalidomide, dapsone, colchicine and cyclophosphamide) are reviewed in this final article.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here